iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced imaging and radiation therapy for the early identification and treatment of cancer, today announced growing demand, adoption and clinical evidence for its Xoft® Axxent® Electronic Brachytherapy System® for the treatment of early-stage breast cancer and non-melanoma skin cancer.
“We are seeing significant growth in our radiation therapy business across multiple therapeutic areas, active enrollment in post-market studies and a growing body of clinical data in support of the Xoft System, all of which are driving momentum for the company,” said Ken Ferry, President and CEO of iCAD. “The use of our system to treat non-melanoma skin cancer continues to expand rapidly, evidenced by more than 3,000 patients treated to date using the Xoft System, the only electronic brachytherapy system with peer-reviewed published data for this application.”
Leading Medical Centers Adopt the Xoft System
Some of the latest medical centers to adopt the Xoft System include City of Hope (Duarte, Calif.), Staten Island University Hospital (Staten Island, NY), Strimling Dermatology, Laser & Vein Institute (Las Vegas, Nev.), Mobile Skin Cancer Radiation Specialists (Phoenix, Ariz.) and University of Oklahoma Breast Institute (Oklahoma City, Okla.)Growing Clinical Evidence A prospective, multi-center, clinical trial evaluating the safety, efficacy and cosmetic outcomes associated with Intraoperative Radiation Therapy (IORT) for early-stage breast cancer with the Xoft System, continues to gain momentum. To date, 19 medical centers across the U.S. have enrolled more than 180 patients. “The Xoft System allows us to offer our patients with early-stage breast cancer an advanced treatment option that eliminates many of the burdens commonly associated with post-surgical radiation treatment,” said Laura Kruper, M.D., Breast Surgeon and Director of the Rita Cooper Finkel and J. William Finkel Women’s Health Center at City of Hope Hospital. “The Xoft System delivers a full course of radiation therapy at the time of lumpectomy surgery, minimizing exposure to surrounding healthy tissue and organs and replacing weeks of follow up treatment with just one dose.”